Pyrvinium

CHEMBL1201303 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
382.5 g/mol
LogP
5.9
Phase
4

Pyrvinium is a cyanine dye antiparasitic agent that inhibits the NADH-fumarate reductase mitochondrial electron transport chain of helminths, disrupting their glucose uptake and aerobic metabolism, causing paralysis and death of the parasite. It is used for the treatment of pinworm (enterobiasis) infections, and more recently has been investigated as an antineoplastic agent targeting the Wnt signaling pathway in cancer, including pancreatic cancer.

น้ำหนักโมเลกุล

382.5000 g/mol

LogP

5.90

TPSA

12.10 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1

InChI

InChI=1S/C26H28N3/c1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5/h6-18H,1-5H3/q+1

Molecular Formula

C26H28N3+

HBD / HBA

- / 1

พันธะที่หมุนได้

4

อะตอมหนัก

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Pyrvinium is a cyanine dye antiparasitic agent that inhibits the NADH-fumarate reductase mitochondrial electron transport chain of helminths, disrupting their glucose uptake and aerobic metabolism, causing paralysis and death of the parasite. It is used for the treatment of pinworm (enterobiasis) infections, and more recently has been investigated as an antineoplastic agent targeting the Wnt signaling pathway in cancer, including pancreatic cancer.

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Yes, Pyrvinium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201303. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5281035. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.